Patients with a history of hepatic sinusoid obstructive syndrome (veno-occlusive disease) within the prior  months
History of reversible posterior leukoencephalopathy syndrome (RPLS)
Trisomy  (Down syndrome)
Patients known to have one of the following concomitant genetic syndromes: Down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome
Patients with Down syndrome
Patients with Down syndrome are not eligible
Down syndrome
Patients with down syndrome are excluded from this study
Patients with known symptomatic Fanconi anemia (FA), ataxia-telangiectasia (A-T) syndrome, Bloom syndrome (BS) and Nijmegen breakage syndrome (NBS) are not eligible (asymptomatic carriers are acceptable)
History of sarcoidosis syndrome
Patients must not have evidence or history of veno-occlusive disease or sinusoidal obstruction syndrome
POEMS syndrome
Mycosis fungoide/Sezary syndrome
History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.
History of nephrotic syndrome
Patients with nevoid BCC syndrome (Gorlin syndrome) should not enroll in this study
Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis.
Any history of serotonin syndrome (SS) after receiving  or more serotonergic drugs
Patients with Downs syndrome
Patients with Down syndrome
History of hemolytic-uremic syndrome.
Erythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson syndrome
History of sarcoidosis syndrome
History of multiple sclerosis or other demyelinating disease and/or Eaton-Lambert syndrome (para-neoplastic syndrome)
Any history of serotonin syndrome after receiving serotonergic drugs
Documented history of carcinoid syndrome
Subjects with history of or active symptoms of carcinoid syndrome
Any history of serotonin syndrome (SS) after receiving serotonergic drugs
Known reversible posterior leukoencephalopathy syndrome (RPLS)
History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome or any other known bone marrow failure syndrome
History of multiple sclerosis or other demyelinating disease, Eaton-Lambert syndrome (para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last  months, or alcoholic liver disease;
Carotid sinus hypersensitivity syndrome.
Any history of serotonin syndrome (SS) after receiving serotonergic drugs
Documented history of capillary leak syndrome within  months of study enrollment.
History of sarcoidosis syndrome
Patients with respiratory distress syndrome
Has any history of serotonin syndrome after receiving  or more serotonergic drugs
Has history of reversible posterior leukoencephalopathy syndrome
History of sarcoidosis syndrome
Has a paraneoplastic syndrome other than syndrome of inappropriate antidiuretic hormone secretion (SIADH) (hyponatremia)
History of sarcoidosis syndrome
history of erythema multiforme, toxic epidermal necrolysis or Stevens-Johnson syndrome;
Has active cytokine release syndrome from CTL infusion
Down syndrome
Individuals with Down syndrome
History of serotonergic syndrome
Any history of Stevens-Johnson syndrome
Patients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligible
Subjects with Gorlin syndrome
Patients with concomitant genetic syndrome: patients with Down syndrome, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome
No history of Stevens Johnsons syndrome, toxic epidermal necrolysis (TEN)s syndrome, or motor neuropathy
RANDOMIZED PHASE II (ARMS K AND L): No history of Stevens Johnsons syndrome, TENs syndrome, or motor neuropathy
Patients with active Richter's syndrome (>% large B-cells in marrow).
History of multiple sclerosis or other demyelinating disease, Eaton-Lambert syndrome (para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last  months, or alcoholic liver disease;
Must not have a serotonin-secreting carcinoid tumor or a prior history of drug-induced serotonin syndrome
POEMS syndrome
Patients with HNPCC (Lynch Syndrome)
Has any history of serotonin syndrome after receiving serotonergic drugs
Down syndrome
Kostmann syndrome
Shwachman syndrome
Patient has a history of Stevens-Johnson-Syndrome (SJS) or Toxic Epidermal Necroloysis (TEN)
Subject has Acute Respiratory Distress Syndrome (ARDS)
Patients known to have one of the following concomitant genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndrome
Diagnosis of Down syndrome (Trisomy )
Patients with any of the following diagnoses:\r\n* Acute promyelocytic leukemia (APL)\r\n* Down syndrome\r\n* Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome\r\n* Wilson's disease and any other disorder of copper metabolism\r\n* Juvenile myelomonocytic leukemia (JMML)
Radiosensitivity syndrome (scleroderma, dermatomyositis, other genetic syndrome that predisposes to adverse radiotherapy complications)
Patients with a family history or Li-Fraumeni syndrome will not be eligible
Patients who have experienced bowel perforation, neurologic involvement, Guillain Barr syndrome, Myasthenia Gravis, Steven Johnson syndrome and other intractable events or grade  non-laboratory toxicity
Patients with a history of toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome are excluded
Subject has Down syndrome.
Patients with concomitant genetic syndrome: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down Syndrome will not be excluded.
History of Stevens-Johnson syndrome or toxic epidermal necrolysis syndrome.
Richter syndrome
Patients with peripheral arterial disease with intermittent claudication or Leriches Syndrome
Subjects who have history of toxic epidermal necrolysis or Stevens-Johnson syndrome;
Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement; or
Had prior serotonin syndrome
Patients with concomitant genetic syndrome: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down Syndrome will not be excluded.
Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement for ?  months prior to signing the ICF; or
Known history or presence of Sweet Syndrome at screening
History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.
No history of erythema multiforme, toxic epidermal necrolysis or Stevens-Johnson syndrome
POEMS syndrome
Any history of serotonin syndrome after receiving serotonergic drugs.
History of sarcoidosis syndrome
Have ongoing or recent (? months) hepatorenal syndrome.
Patients who have a known inherited syndrome as the cause for hormone over secretion.
Patients with Cushing's syndrome due to ectopic ACTH secretion or ACTH-independent (adrenal) Cushing's syndrome.
Have active metabolic or digestive illnesses such as malabsorptive disorders (Crohns, Celiac disease, irritable bowel syndrome [IBS]), renal insufficiency, hepatic insufficiency, cachexia, or short bowel syndrome
Patients with any of the following constitutional conditions are not eligible:\r\n* Fanconi anemia\r\n* Shwachman syndrome\r\n* Any other known bone marrow failure syndrome\r\n* Patients with constitutional trisomy  or with constitutional mosaicism of trisomy  \r\nNote: enrollment may occur pending results of clinically indicated studies to exclude these conditions
Known to have a hypercoagulability syndrome (e.g.: antithrombin III, deficiency, anticardiolipin syndrome etc)
Patients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocytic leukemia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other bone marrow failure syndromes are not eligible
History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome or any other known bone marrow failure syndrome
Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi syndrome or renal tubular acidosis
Cushings syndrome
Li-Fraumeni Syndrome
History of reversible posterior leukoencephalopathy syndrome (RPLS)
History of sarcoidosis syndrome.
Down Syndrome
History of sarcoidosis syndrome
Diagnosis of Waldenstrom's macroglobulinemia, POEMS syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome
Individuals with Down syndrome
Carcinoid Syndrome
Has a known history of, or active, neurologic paraneoplastic syndrome
Nephrotic syndrome
Patients with a known mutation in p (Li Fraumeni syndrome)
Down syndrome
Kostmann syndrome
Shwachman syndrome
Concomitant genetic syndrome or other known bone marrow failure syndrome
Down syndrome
Patients with Down syndrome are excluded.
Neurologic disease including multiple sclerosis, Eaton-Lambert syndrome, demyelination
Patients with nevoid BCC syndrome (Gorlin syndrome) may enroll in this study but must meet the criteria for locally advanced or metastatic disease listed above
Szary syndrome
Subjects with posterior leukoencephalopathy syndrome
History of neurological conditions that would confound assessment of treatment-emergent neuropathy other than =< grade  peripheral neuropathy including multiple sclerosis or other demyelinating disease and/or Eaton-Lambert syndrome (para-neoplastic syndrome); diabetes is allowed
Subjects who have Gorlin syndrome
Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome;
History of sarcoidosis syndrome
Patients with a family history or Li-Fraumeni syndrome will not be eligible
Patient has Down syndrome
Patients with known history of Trisomy  (Down Syndrome), history of congenital immunodeficiency or inherited marrow failure disorder.
Nephrotic syndrome
Patients with a known germline mutation of PTPN (Noonans Syndrome) are not eligible
Immediate family member with a known or suspected Familial Cancer Syndrome (including but not limited to hereditary breast and ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrome and familial adenomatous polyposis).
History of congenital platelet function defect (e.g., Bernard-Soulier syndrome, Chediak-Higashi syndrome, Glanzmann thrombasthenia, storage pool defect)
History of hepatic sinusoid obstructive syndrome (venoocculsive disease) within the prior  months.
Diagnosis of smoldering multiple myeloma, Waldenstrom's macroglobulinemia, POEMS syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome
Has known gastrointestinal condition or procedure that could interfere with swallowing or the oral absorption of tolerance of IXAZOMIB - Diagnosis of smoldering multiple myeloma, Waldenstrom's macroglobulinemia, POEMS syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome
Patients with an immunodeficiency syndrome
Patients diagnosed with Sezary syndrome; Sezary syndrome is equivalent to mycosis fungoides that develops to stage IVA/B with B (high blood tumor burden) involvement, and as such requires a more aggressive treatment regimen than Valchlor or TSEBT
Patients with any of the following diagnoses are not eligible:\r\n* Acute promyelocytic leukemia (APL)\r\n* Down syndrome\r\n* Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome\r\n* Wilson's disease and any other disorder of copper metabolism\r\n* Juvenile myelomonocytic leukemia (JMML)
Active or a history of Tourettes syndrome or tic disorder
Patients with Down syndrome
Patients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocytic leukemia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other bone marrow failure syndromes are not eligible
Known Mirizzi syndrome.
History of irritable bowel syndrome (IBS)
Patients with Sjogren's syndrome
Ongoing or recent hepatorenal syndrome.
Patients with diagnosis of chronic fatigue syndrome (CFS)
Patients with a diagnosis of obesity hypoventilation syndrome
History of irritable bowel syndrome (IBS)
Diagnosed or suspected vasospastic disease such as Raynauds syndrome;
Myelodysplatic Syndrome
History of Guillain-Barre syndrome
History of Guillain-Barre syndrome
Have a history of Guillain-Barre syndrome (GBS)
Familial short QT syndrome
Down syndrome
Short gut syndrome
History of atrophic gastritis, pernicious anemia, or Zollinger-Ellison syndrome
Subjects who have Gorlins syndrome
Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement for ?  months; or
Diagnosis of Down's Syndrome
Individuals with Li Fraumeni syndrome defined as one of the following:\r\n* Carriers of a germline protein  (p) mutation\r\n* Members of families meeting classic Li-Fraumeni syndrome (LFS) criteria by family history without an identifiable p mutation\r\n* Obligate carrier by pedigree (these individuals can be offered testing but are still eligible if they defer); the following examples describe obligate carriers by pedigree\r\n** A child of a parent with known p mutation that is diagnosed with cancer\r\n** An individual with a sibling and a child who are p positive OR\r\n* Individuals with an inherited cancer predisposition syndrome as defined by one of the following:\r\n** Hereditary retinoblastoma with a germline retinoblastoma (Rb) mutation\r\n** Diagnosis of hereditary paraganglioma/pheochromocytoma syndrome with a germline succinate dehydrogenase (SDH) mutation\r\n** Diagnosis of multiple endocrine neoplasia, type  or , with a germline multiple endocrine neoplasia (MEN) mutation\r\n** New diagnosis of opsoclonus-myoclonus with a negative cancer work-up upon presentation of symptoms\r\n** Familial neuroblastoma with a germline anaplastic lymphoma kinase (ALK) mutation\r\n** Rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation (ROHHAD syndrome) or congenital central hypoventilation syndrome (CCHS) with or without a germline pairedlike homeobox B (PHOX B) mutation\r\n** Von Hippel-Lindau with a Von Hippel-Lindau (VHL) mutation\r\n** Women with an abnormal cell-free deoxyribonucleic acid (DNA) test (i.e. a non-invasive prenatal test [NIPT] to detect chromosomal abnormalities) and no cancer diagnosis\r\n** Other rare cancer predisposition syndromes at the discretion of the treating physician and study physicians\r\n* IF APPLICABLE: individuals with any of the above-listed cancer predisposition syndromes (apart from Li Fraumeni syndrome) are likewise eligible in the absence of a known mutation if they are an obligate carrier by pedigree
Individuals with Li Fraumeni syndrome defined as one of the following:\r\n* Carriers of a germline p mutation OR\r\n* Members of families meeting classic LFS criteria by family history without an identifiable p mutation OR\r\n* Obligate carrier by pedigree (these individuals can be offered testing but are still eligible if they defer); the following examples describe obligate carriers by pedigree\r\n** A child of a parent with known p mutation that is diagnosed with cancer\r\n** An individual with a sibling and a child who are p positive OR\r\n* Individuals with an inherited cancer predisposition syndrome as defined by one of the following:\r\n** Hereditary retinoblastoma with a germline Rb mutation\r\n** Diagnosis of hereditary paraganglioma/pheochromocytoma syndrome with a germline SDH mutation\r\n** Diagnosis of multiple endocrine neoplasia, type  or , with a germline MEN mutation\r\n** New diagnosis of opsoclonus-myoclonus with a negative cancer work-up upon presentation of symptoms\r\n** Familial neuroblastoma with a germline ALK mutation\r\n** Rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation (ROHHAD syndrome) or congenital central hypoventilation syndrome (CCHS) with or without a germline PHOX B mutation\r\n** Von Hippel-Lindau with a VHL mutation\r\n** Other rare cancer predisposition syndrome at the discretion of the treating physician and study physicians\r\n* IF APPLICABLE: individuals with any of the above-listed cancer predisposition syndromes (apart from Li Fraumeni syndrome) are likewise eligible in the absence of a known mutation if they are an obligate carrier by pedigree
History of Stevens-Johnson syndrome
History of Stevens-Johnson syndrome
Patients with respiratory distress syndrome
PATIENT: Patients with respiratory distress syndrome
Patients with unstable cardiopulmonary conditions or respiratory distress syndrome
History of Stevens Johnsons syndrome, toxic epidermal necrolysis syndrome (TENs) or motor neuropathy
Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi syndrome or renal tubular acidosis
Patients with respiratory distress syndrome
Patients with respiratory distress syndrome
History of Stevens-Johnson syndrome or toxic epidermal necrolysis syndrome.
History of Guillain-Barre syndrome or Stevens-Johnson syndrome
